Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs

Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.